TT 138
Alternative Names: MN-246; TT-138Latest Information Update: 18 Apr 2016
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Small molecules; Urologics
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Urinary frequency; Urinary incontinence
Most Recent Events
- 18 Apr 2016 Discontinued - Phase-I for Urinary frequency in USA (PO)
- 18 Apr 2016 Discontinued - Phase-I for Urinary incontinence in Canada (PO)
- 18 Apr 2016 Discontinued - Phase-I for Urinary incontinence in USA (PO)